TGFB1 and neoplasm: EZH2 inhibition, either pharmacologically or genetically, destabilizes FOXP3 expression in Treg cells and specifically reprograms tumour- infiltrating Treg cells through driving the expression pro-inflammatory genes (e.g., IL-2) while inhibiting key immunosuppressive genes such as IL-10 and TGF-β (43).